HER2阳性-话题@MedSci

#HER2阳性#

183篇内容 | 2219人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2174870, encodeId=b5f521e48703a, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a> <a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a> <a href='/topic/show?id=ec8c1085e86c' target=_blank style='color:#2F92EE;'>#双靶点抗HER2治疗#</a>, objectTitle=病例分享 | 综合治疗Her-2阳性转移性结肠癌达NED一例, objectType=article, longId=804905, objectId=aeab80490598, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696894056775_4754896.jpeg, objectUrl=/article/show_article.do?id=aeab80490598, replyNumber=0, likeNumber=40, createdTime=2023-12-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=aeab80490598, moduleTitle=病例分享 | 综合治疗Her-2阳性转移性结肠癌达NED一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeab80490598)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2172152, encodeId=edbf21e2152fd, content=<a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a>联合<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>和化疗一线治疗<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>晚期<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>具有令人惊喜的疗效结果。, objectTitle=疾病控制率100%！《柳叶刀》子刊：胃癌一线治疗有望迎来重磅疗法！, objectType=article, longId=801776, objectId=c363801e764a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/type2diabetes-s2-stomach-and-pancreas.jpg, objectUrl=/article/show_article.do?id=c363801e764a, replyNumber=0, likeNumber=32, createdTime=2023-11-30, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=c363801e764a, moduleTitle=疾病控制率100%！《柳叶刀》子刊：胃癌一线治疗有望迎来重磅疗法！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c363801e764a)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2118786, encodeId=5ece2118e862e, content=<a href='/topic/show?id=897f10555688' target=_blank style='color:#2F92EE;'>#德喜曲妥珠单抗#</a>（<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>，<a href='/topic/show?id=2f1862e434' target=_blank style='color:#2F92EE;'>#DS-8201#</a>）II期临床数据在泛HER2表达晚期<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>的持久反应，Enhertu（5.4mg/kg）治疗HER2表达肿瘤的疗效和安全性，包括<a href='/topic/show?id=a9ef83546d6' target=_blank style='color:#2F92EE;'>#胆道癌#</a>、<a href='/topic/show?id=843a85e9421' target=_blank style='color:#2F92EE;'>#膀胱癌#</a>、<a href='/topic/show?id=146246308d1' target=_blank style='color:#2F92EE;'>#宫颈癌#</a>、<a href='/topic/show?id=942b4516096' target=_blank style='color:#2F92EE;'>#子宫内膜癌#</a>、<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>、<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>和罕见肿瘤。<a href='/topic/show?id=e0df9e832a7' target=_blank style='color:#2F92EE;'>#阿斯利康#</a>和<a href='/topic/show?id=446ae5737da' target=_blank style='color:#2F92EE;'>#第一三共#</a>会收获很多，<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>大概率会批准Enhertu为HER2阳性<a href='/topic/show?id=fdfe10555ef9' target=_blank style='color:#2F92EE;'>#泛癌肿适应症#</a>！这就牛了，是<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>第一个靶向药物。, objectTitle=德喜曲妥珠单抗（Enhertu）II期临床数据在泛HER2表达晚期实体瘤的持久反应（DESTINY-PanTumor02研究）, objectType=article, longId=762351, objectId=656ce623519a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230111/c366160a3bd44df480b7eb8f2aa7eb36.jpg, objectUrl=/article/show_article.do?id=656ce623519a, replyNumber=1, likeNumber=132, createdTime=2023-03-11, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=656ce623519a, moduleTitle=德喜曲妥珠单抗（Enhertu）II期临床数据在泛HER2表达晚期实体瘤的持久反应（DESTINY-PanTumor02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=656ce623519a)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1308625, encodeId=4f1313086258a, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性晚期乳腺癌治疗进展文献回顾, objectType=article, longId=736701, objectId=3186e367017a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3186e367017a, replyNumber=0, likeNumber=64, createdTime=2022-08-25, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3186e367017a, moduleTitle=HER2阳性晚期乳腺癌治疗进展文献回顾, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3186e367017a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308624, encodeId=9d9f1308624ca, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=张剑主任：HER2阳性乳腺癌最新临床进展, objectType=article, longId=736699, objectId=c0b4e3669906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0b4e3669906, replyNumber=0, likeNumber=65, createdTime=2022-08-25, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0b4e3669906, moduleTitle=张剑主任：HER2阳性乳腺癌最新临床进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0b4e3669906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308623, encodeId=cb8b1308623b1, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=王涛教授：HER2阳性晚期乳腺癌治疗进展, objectType=article, longId=736318, objectId=aac6e3631804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aac6e3631804, replyNumber=0, likeNumber=64, createdTime=2022-08-21, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aac6e3631804, moduleTitle=王涛教授：HER2阳性晚期乳腺癌治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aac6e3631804)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308622, encodeId=1800130862295, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=非HER2阳性的乳腺癌患者辅助治疗, objectType=article, longId=736057, objectId=8bf7e36057de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8bf7e36057de, replyNumber=0, likeNumber=0, createdTime=2022-08-18, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8bf7e36057de, moduleTitle=非HER2阳性的乳腺癌患者辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8bf7e36057de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308621, encodeId=68aa1308621b3, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=2022年ASCO指南更新！晚期HER2阳性乳腺癌治疗如何排兵布阵最好？, objectType=article, longId=734750, objectId=cce2e3475091, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cce2e3475091, replyNumber=0, likeNumber=64, createdTime=2022-08-06, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cce2e3475091, moduleTitle=2022年ASCO指南更新！晚期HER2阳性乳腺癌治疗如何排兵布阵最好？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cce2e3475091)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308620, encodeId=ffdb13086201e, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=J Clin Oncol：阿特珠单抗联合新辅助化疗治疗HER2阳性早期乳腺癌, objectType=article, longId=731832, objectId=22efe318328a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22efe318328a, replyNumber=0, likeNumber=51, createdTime=2022-07-10, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22efe318328a, moduleTitle=J Clin Oncol：阿特珠单抗联合新辅助化疗治疗HER2阳性早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22efe318328a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308619, encodeId=79011308619ff, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=ASCO指南又双叒有更新啦！HER2阳性晚期乳腺癌脑转移如何处理？一图看清！, objectType=article, longId=728535, objectId=b917e285354b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b917e285354b, replyNumber=0, likeNumber=61, createdTime=2022-06-04, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b917e285354b, moduleTitle=ASCO指南又双叒有更新啦！HER2阳性晚期乳腺癌脑转移如何处理？一图看清！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b917e285354b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308618, encodeId=f21e130861831, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=ASCO指南重磅更新！对于HER2阳性晚期乳腺癌，最佳治疗到底是什么？最新最全循证依据也都在这了！, objectType=article, longId=728444, objectId=eacae28444f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eacae28444f5, replyNumber=0, likeNumber=60, createdTime=2022-06-03, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eacae28444f5, moduleTitle=ASCO指南重磅更新！对于HER2阳性晚期乳腺癌，最佳治疗到底是什么？最新最全循证依据也都在这了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eacae28444f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308617, encodeId=bd9e130861ef2, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Trastuzumab Deruxtecan治疗HER2阳性乳腺癌效果优于trastuzumab emtansine, objectType=article, longId=725405, objectId=f586e25405ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f586e25405ed, replyNumber=0, likeNumber=49, createdTime=2022-04-27, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f586e25405ed, moduleTitle=Trastuzumab Deruxtecan治疗HER2阳性乳腺癌效果优于trastuzumab emtansine, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f586e25405ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308616, encodeId=b3171308616a5, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌, objectType=article, longId=301648, objectId=93a0301648a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93a0301648a6, replyNumber=0, likeNumber=41, createdTime=2022-03-27, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93a0301648a6, moduleTitle=NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93a0301648a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308615, encodeId=62f31308615d2, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益, objectType=article, longId=301447, objectId=d0c230144eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0c230144eb9, replyNumber=0, likeNumber=57, createdTime=2022-03-24, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0c230144eb9, moduleTitle=Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0c230144eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308614, encodeId=3733130861411, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=BMC Cancer：中肿团队HER2阳性难治性转移性乳腺癌转化模式疗法疗效显著, objectType=article, longId=300955, objectId=f42b30095557, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f42b30095557, replyNumber=0, likeNumber=0, createdTime=2022-03-18, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f42b30095557, moduleTitle=BMC Cancer：中肿团队HER2阳性难治性转移性乳腺癌转化模式疗法疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f42b30095557)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308613, encodeId=e64f130861359, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet Oncol：Pyrotinib联合卡培他滨治疗HER2阳性乳腺癌患者脑转移的疗效, objectType=article, longId=295056, objectId=30a9295056e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30a9295056e6, replyNumber=0, likeNumber=50, createdTime=2022-02-04, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30a9295056e6, moduleTitle=Lancet Oncol：Pyrotinib联合卡培他滨治疗HER2阳性乳腺癌患者脑转移的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30a9295056e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308612, encodeId=68e513086123c, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Front Oncol：TMB状态对抗HER2治疗在HER2阳性晚期胃癌(AGC)的疗效的影响, objectType=article, longId=221553, objectId=243b2215533b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=243b2215533b, replyNumber=0, likeNumber=37, createdTime=2021-12-06, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=243b2215533b, moduleTitle=Front Oncol：TMB状态对抗HER2治疗在HER2阳性晚期胃癌(AGC)的疗效的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=243b2215533b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308611, encodeId=48da13086116a, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索, objectType=article, longId=221293, objectId=c4e6221293db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4e6221293db, replyNumber=0, likeNumber=68, createdTime=2021-12-01, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4e6221293db, moduleTitle=Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4e6221293db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308610, encodeId=97b8130861064, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=221117, objectId=796122111e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=796122111e42, replyNumber=0, likeNumber=35, createdTime=2021-11-28, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=796122111e42, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=796122111e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308609, encodeId=df51130860995, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索, objectType=article, longId=220088, objectId=133b22008853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133b22008853, replyNumber=0, likeNumber=47, createdTime=2021-11-12, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133b22008853, moduleTitle=Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=133b22008853)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阳性

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#结直肠癌# #HER2阳性# #双特异性抗体# #双靶点抗HER2治疗#

病例分享 | 综合治疗Her-2阳性转移性结肠癌达NED一例

2023-12-14发表于上海

(审核中...)

前往app查看评论内容

#吡咯替尼#联合#卡瑞利珠单抗#和化疗一线治疗#HER2阳性#晚期#胃癌#具有令人惊喜的疗效结果。

疾病控制率100%！《柳叶刀》子刊：胃癌一线治疗有望迎来重磅疗法！

2023-11-30发表于威斯康星

showtest (审核中...)

前往app查看评论内容

全文收起 #德喜曲妥珠单抗#（#Enhertu#，#DS-8201#）II期临床数据在泛HER2表达晚期#实体瘤#的持久反应，Enhertu（5.4mg/kg）治疗HER2表达肿瘤的疗效和安全性，包括#胆道癌#、#膀胱癌#、#宫颈癌#、#子宫内膜癌#、#卵巢癌#、#胰腺癌#和罕见肿瘤。#阿斯利康#和#第一三共#会收获很多，#FDA#大概率会批准Enhertu为HER2阳性#泛癌肿适应症#！这就牛了，是#HER2阳性#第一个靶向药物。

德喜曲妥珠单抗（Enhertu）II期临床数据在泛HER2表达晚期实体瘤的持久反应（DESTINY-PanTumor02研究）

2023-03-11发表于上海

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性晚期乳腺癌治疗进展文献回顾

2022-08-25

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

张剑主任：HER2阳性乳腺癌最新临床进展

2022-08-25

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

王涛教授：HER2阳性晚期乳腺癌治疗进展

2022-08-21

爆笑小医 (审核中...)

前往app查看评论内容

#HER2阳性#

非HER2阳性的乳腺癌患者辅助治疗

2022-08-18

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

2022年ASCO指南更新！晚期HER2阳性乳腺癌治疗如何排兵布阵最好？

2022-08-06

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

J Clin Oncol：阿特珠单抗联合新辅助化疗治疗HER2阳性早期乳腺癌

2022-07-10

docwu2019 (审核中...)

前往app查看评论内容

#HER2阳性#

ASCO指南又双叒有更新啦！HER2阳性晚期乳腺癌脑转移如何处理？一图看清！

2022-06-04

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

ASCO指南重磅更新！对于HER2阳性晚期乳腺癌，最佳治疗到底是什么？最新最全循证依据也都在这了！

2022-06-03

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Trastuzumab Deruxtecan治疗HER2阳性乳腺癌效果优于trastuzumab emtansine

2022-04-27

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌

2022-03-27

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益

2022-03-24

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

BMC Cancer：中肿团队HER2阳性难治性转移性乳腺癌转化模式疗法疗效显著

2022-03-18

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet Oncol：Pyrotinib联合卡培他滨治疗HER2阳性乳腺癌患者脑转移的疗效

2022-02-04

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Front Oncol：TMB状态对抗HER2治疗在HER2阳性晚期胃癌(AGC)的疗效的影响

2021-12-06

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索

2021-12-01

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2021-11-28

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索

2021-11-12

科室
- - 订阅+
  - 更多科室
工具
服务